News & Events
< Back to News Overview
ChemGenex to Present at Canaccord Adams' 27th Global Growth Conference
07 / 08 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that it will deliver a presentation at the 27th Annual Canaccord Adams Global Growth Conference in Boston, Massachusetts. Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex, is scheduled to present to leading institutional investment representatives at 10am on Thursday, August 9, 2007, at the InterContinental Boston.
"We look forward to showcasing ChemGenex to international investors at this year's Growth Conference," said Dr Collier. "This is an ideal venue at which to provide an update of our registrationdirected clinical program in chronic myeloid leukemia (CML) patients with the T315I BCR-ABL point mutation and other corporate activities."
An audio webcast of the presentation will be available from the company''s website, www.chemgenex.com one hour after the completion of the presentation, and will be available for 90 days after the conference.
The Canaccord Adams Global Growth Conference is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Many of the presenting public companies are covered by Canaccord Adams' global team of equity analysts.
"We look forward to showcasing ChemGenex to international investors at this year's Growth Conference," said Dr Collier. "This is an ideal venue at which to provide an update of our registrationdirected clinical program in chronic myeloid leukemia (CML) patients with the T315I BCR-ABL point mutation and other corporate activities."
An audio webcast of the presentation will be available from the company''s website, www.chemgenex.com one hour after the completion of the presentation, and will be available for 90 days after the conference.
The Canaccord Adams Global Growth Conference is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Many of the presenting public companies are covered by Canaccord Adams' global team of equity analysts.